• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

白细胞介素-17,COVID-19 严重程度的唾液生物标志物。

Interleukin-17, a salivary biomarker for COVID-19 severity.

机构信息

Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates.

Pharmacy Department, Dubai Health Authority, Dubai, United Arab Emirates.

出版信息

PLoS One. 2022 Sep 22;17(9):e0274841. doi: 10.1371/journal.pone.0274841. eCollection 2022.

DOI:10.1371/journal.pone.0274841
PMID:36136963
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9498944/
Abstract

OBJECTIVES

T-helper 17 cell-mediated response and their effector IL-17 cytokine induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a major cause of COVID-19 disease severity and death. Therefore, the study aimed to determine if IL-17 level in saliva mirrors its circulatory level and hence can be used as a non-invasive biomarker for disease severity.

METHODS

Interleukin-17 (IL-17) level was evaluated by ELISA in saliva and blood of 201 adult COVID-19 patients with different levels of severity. The IL-17 saliva level was also associated with COVID-19 disease severity, and need for mechanical ventilation and/or death within 29 days after admission of severe COVID-19 patients.

RESULTS

We found that IL-17 level in saliva of COVID-19 patients reflected its circulatory level. High IL-17 level in saliva was associated with COVID-19 severity (P<0.001), need for mechanical ventilation (P = 0.002), and/or death by 29 days (P = 0.002), after adjusting for patients' demographics, comorbidity, and COVID-19 serum severity markers such as D-Dimer, C-reactive protein, and ferritin.

CONCLUSION

We propose that saliva IL-17 level could be used as a biomarker to identify patients at risk of developing severe COVID-19.

摘要

目的

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染引起的辅助性 T 细胞 17 细胞介导的反应及其效应细胞因子白细胞介素-17(IL-17)是导致 COVID-19 疾病严重程度和死亡的主要原因。因此,本研究旨在确定唾液中的 IL-17 水平是否反映其循环水平,因此是否可以用作疾病严重程度的非侵入性生物标志物。

方法

通过 ELISA 法评估 201 名不同严重程度的成年 COVID-19 患者的唾液和血液中的白细胞介素-17(IL-17)水平。IL-17 唾液水平还与 COVID-19 疾病严重程度、机械通气需求以及 29 天内严重 COVID-19 患者的死亡相关。

结果

我们发现 COVID-19 患者唾液中的 IL-17 水平反映了其循环水平。高唾液 IL-17 水平与 COVID-19 严重程度相关(P<0.001),与需要机械通气(P = 0.002)和/或 29 天内死亡相关(P = 0.002),调整了患者的人口统计学、合并症以及 COVID-19 血清严重程度标志物如 D-二聚体、C 反应蛋白和铁蛋白。

结论

我们提出唾液 IL-17 水平可以用作识别有发生严重 COVID-19 风险的患者的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a97/9498944/ca1895479a04/pone.0274841.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a97/9498944/315d4a71eba3/pone.0274841.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a97/9498944/ca1895479a04/pone.0274841.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a97/9498944/315d4a71eba3/pone.0274841.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a97/9498944/ca1895479a04/pone.0274841.g002.jpg

相似文献

1
Interleukin-17, a salivary biomarker for COVID-19 severity.白细胞介素-17,COVID-19 严重程度的唾液生物标志物。
PLoS One. 2022 Sep 22;17(9):e0274841. doi: 10.1371/journal.pone.0274841. eCollection 2022.
2
Upregulation of interleukin-19 in saliva of patients with COVID-19.COVID-19 患者唾液中白细胞介素-19 的上调。
Sci Rep. 2022 Sep 26;12(1):16019. doi: 10.1038/s41598-022-20087-w.
3
Immunological and biochemical biomarker alterations among SARS-COV-2 patients with varying disease phenotypes in Uganda.乌干达不同疾病表型的 SARS-COV-2 患者的免疫和生化生物标志物改变。
BMC Infect Dis. 2023 Dec 6;23(1):857. doi: 10.1186/s12879-023-08854-0.
4
Early increase of serum ferritin among COVID-19 patients is associated with need of invasive mechanical ventilation and with in-hospital death.COVID-19 患者血清铁蛋白早期升高与需要有创机械通气和院内死亡相关。
Infect Dis (Lond). 2022 Nov;54(11):810-818. doi: 10.1080/23744235.2022.2101691. Epub 2022 Jul 19.
5
Secretory Phospholipase A2 and Interleukin-6 Levels as Predictive Markers of the Severity and Outcome of Patients with COVID-19 Infections.分泌型磷脂酶 A2 和白细胞介素 6 水平作为预测 COVID-19 感染患者严重程度和结局的标志物。
Int J Mol Sci. 2023 Mar 14;24(6):5540. doi: 10.3390/ijms24065540.
6
Salivary Ferritin Changes in Patients with COVID-19.新型冠状病毒肺炎患者唾液铁蛋白的变化。
Int J Environ Res Public Health. 2021 Dec 21;19(1):41. doi: 10.3390/ijerph19010041.
7
The intercorrelations between blood levels of ferritin, sCD163, and IL-18 in COVID-19 patients and their association to prognosis.COVID-19 患者血清铁蛋白、sCD163 和 IL-18 水平的相关性及其与预后的关系。
Immunol Res. 2022 Dec;70(6):817-828. doi: 10.1007/s12026-022-09312-w. Epub 2022 Oct 12.
8
Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.利用 IL-2R/淋巴细胞预测 COVID-19 患者的临床进展。
Clin Exp Immunol. 2020 Jul;201(1):76-84. doi: 10.1111/cei.13450. Epub 2020 May 15.
9
Interleukin-6 (IL-6) as a Predictor of Clinical Outcomes in Patients with COVID-19.白细胞介素-6(IL-6)作为 COVID-19 患者临床结局的预测因子。
Clin Lab. 2023 Jun 1;69(6). doi: 10.7754/Clin.Lab.2022.220741.
10
The study of serum hsCRP, ferritin, IL-6 and plasma D-dimer in COVID-19: a retrospective study.新型冠状病毒肺炎患者血清超敏C反应蛋白、铁蛋白、白细胞介素-6及血浆D-二聚体的研究:一项回顾性研究
Horm Mol Biol Clin Investig. 2022 Mar 31;43(3):337-344. doi: 10.1515/hmbci-2021-0088. eCollection 2022 Sep 1.

引用本文的文献

1
Unravelling the mechanism of action of Huashibaidu formula volatile metabolome for the treatment of COVID-19 and its mutants from the perspectives of network pharmacology and molecular docking.从网络药理学和分子对接角度解析化湿败毒方挥发性代谢组治疗新型冠状病毒肺炎及其突变株的作用机制
Medicine (Baltimore). 2025 May 30;104(22):e42669. doi: 10.1097/MD.0000000000042669.
2
Biomarkers for SARS-CoV-2 infection. A narrative review.新型冠状病毒2019感染的生物标志物。一篇叙述性综述。
Front Med (Lausanne). 2025 Mar 26;12:1563998. doi: 10.3389/fmed.2025.1563998. eCollection 2025.
3
Analysis of Biomarker Levels in Nasopharyngeal Swabs, Serum, and Saliva Across Different Health Conditions.

本文引用的文献

1
Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity.重度哮喘中白细胞介素-19的上调:一种用于评估哮喘严重程度的潜在唾液生物标志物。
ERJ Open Res. 2021 Jul 26;7(3). doi: 10.1183/23120541.00984-2020. eCollection 2021 Jul.
2
SARS-CoV-2 attenuates corticosteroid sensitivity by suppressing DUSP1 expression and activating p38 MAPK pathway.SARS-CoV-2 通过抑制 DUSP1 的表达和激活 p38 MAPK 通路来减弱皮质类固醇的敏感性。
Eur J Pharmacol. 2021 Oct 5;908:174374. doi: 10.1016/j.ejphar.2021.174374. Epub 2021 Jul 22.
3
Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study.
不同健康状况下鼻咽拭子、血清和唾液中生物标志物水平的分析。
Life (Basel). 2025 Feb 19;15(2):324. doi: 10.3390/life15020324.
4
Circulating IL-17F, but not IL-17A, is elevated in severe COVID-19 and leads to an ERK1/2 and p38 MAPK-dependent increase in ICAM-1 cell surface expression and neutrophil adhesion on endothelial cells.循环中的 IL-17F 升高,但 IL-17A 不升高,在重症 COVID-19 中升高,并导致 ERK1/2 和 p38 MAPK 依赖性增加细胞间黏附分子-1(ICAM-1)在血管内皮细胞上的表面表达和中性粒细胞黏附。
Front Immunol. 2024 Oct 18;15:1452788. doi: 10.3389/fimmu.2024.1452788. eCollection 2024.
5
Convergence of inflammatory response: Salivary cytokine dynamics in coronavirus disease 2019 and periodontal disease.炎症反应的趋同:2019冠状病毒病和牙周病中的唾液细胞因子动态变化
J Indian Soc Periodontol. 2024 Jan-Feb;28(1):113-121. doi: 10.4103/jisp.jisp_508_23. Epub 2024 Jun 4.
6
Obesity and diabetes mellitus are associated with SARS-CoV-2 outcomes without influencing signature genes of extrapulmonary immune compartments at the RNA level.肥胖症和糖尿病与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的结果相关,但在RNA水平上不影响肺外免疫区室的特征基因。
Heliyon. 2024 Jan 14;10(2):e24508. doi: 10.1016/j.heliyon.2024.e24508. eCollection 2024 Jan 30.
7
How do deer respiratory epithelial cells weather the initial storm of SARS-CoV-2 WA1/2020 strain?鹿呼吸道上皮细胞如何应对 SARS-CoV-2 WA1/2020 株的最初冲击?
Microbiol Spectr. 2024 Feb 6;12(2):e0252423. doi: 10.1128/spectrum.02524-23. Epub 2024 Jan 8.
8
Effect of antiviral and immunomodulatory treatment on a cytokine profile in patients with COVID-19.抗病毒和免疫调节治疗对 COVID-19 患者细胞因子谱的影响。
Front Immunol. 2023 Jul 6;14:1222170. doi: 10.3389/fimmu.2023.1222170. eCollection 2023.
9
Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic.SARS-CoV-2 感染中的免疫:清晰还是神秘?在全球大流行的第三年的更广阔视角。
Arch Immunol Ther Exp (Warsz). 2023 Feb 21;71(1):7. doi: 10.1007/s00005-023-00673-0.
10
SARS-CoV-2 Infection and Candidate Biomarkers.严重急性呼吸综合征冠状病毒2型感染与候选生物标志物
Eurasian J Med. 2022 Dec;54(Suppl1):16-22. doi: 10.5152/eurasianjmed.2022.22305.
联合使用(干扰素 beta-1b、洛匹那韦/利托那韦和利巴韦林)与法匹拉韦治疗非重症 COVID-19 住院患者:一项队列研究。
PLoS One. 2021 Jun 10;16(6):e0252984. doi: 10.1371/journal.pone.0252984. eCollection 2021.
4
SARS-CoV-2 Switches 'on' MAPK and NFκB Signaling via the Reduction of Nuclear DUSP1 and DUSP5 Expression.严重急性呼吸综合征冠状病毒2通过降低细胞核内双特异性磷酸酶1和双特异性磷酸酶5的表达来“开启”丝裂原活化蛋白激酶和核因子κB信号通路。
Front Pharmacol. 2021 Apr 20;12:631879. doi: 10.3389/fphar.2021.631879. eCollection 2021.
5
Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study.新型冠状病毒肺炎患者疾病严重程度与炎症相关参数的相关性分析:一项回顾性研究。
BMC Infect Dis. 2020 Dec 21;20(1):963. doi: 10.1186/s12879-020-05681-5.
6
Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection.宿主对 SARS-CoV-2 肺部感染的反应的时空异质性。
Nat Commun. 2020 Dec 9;11(1):6319. doi: 10.1038/s41467-020-20139-7.
7
Cytokine profile and disease severity in patients with COVID-19.COVID-19 患者的细胞因子谱与疾病严重程度。
Cytokine. 2021 Jan;137:155323. doi: 10.1016/j.cyto.2020.155323. Epub 2020 Sep 30.
8
In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age.体内抗病毒宿主对 SARS-CoV-2 的转录反应与病毒载量、性别和年龄有关。
PLoS Biol. 2020 Sep 8;18(9):e3000849. doi: 10.1371/journal.pbio.3000849. eCollection 2020 Sep.
9
Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2.用于检测严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的唾液或鼻咽拭子样本
N Engl J Med. 2020 Sep 24;383(13):1283-1286. doi: 10.1056/NEJMc2016359. Epub 2020 Aug 28.
10
An inflammatory cytokine signature predicts COVID-19 severity and survival.炎症细胞因子特征可预测 COVID-19 严重程度和存活情况。
Nat Med. 2020 Oct;26(10):1636-1643. doi: 10.1038/s41591-020-1051-9. Epub 2020 Aug 24.